Chimeric antigen receptor (CAR)-T cell therapy, is a type of cancer immunotherapy that uses genetically altered T-cells to enable them in locating and destroying cancer cells more effectively. Six CAR T-cell therapies have been approved by the Food and Drug Administration (FDA) for the treatment of blood cancers (including lymphomas, some forms of leukemia, multiple myeloma). TriNetX, an Electronic Medical Record (EMR) database combines real time access from healthcare organizations (HCOs) across multiple countries to enable generation of real-world evidence.
This poster, presented at ISPOR 2023, examines the characteristics of patients on CAR-T therapies in HCOs covered by the TriNetX network in the United States (US).
